Histone modifications and specific ncRNAs are associated with lenvatinib resistance; an RNA sequencing study discovered that the lncRNA X-inactive specific transcript (XIST) is highly expressed in lenvatinib-resistant HCC cells and that lncXIST promotes lenvatinib resistance via the activation of the EZH2/NOD2/ERK-signaling axis [211]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.